Seven cases of thromboembolism were found amongst 23 patients treated with thalidomide for myeloma over a total of 141.5 patient treatment months. Five thromboembolic events were venous (two severe) and two arterial. A historical control of 18 similar patients not given thalidomide had one thromboembolism over 289 months. We found no underlying thrombophilic tendency in the affected patients. We suggest that the thalidomide may predispose to thromboembolism at even lower doses than previously reported (mean dose 150 mg). The two most severe thromboses occurred on 100 mg thalidomide alone, not associated with chemotherapy or glucocorticoids. We raise the possibility that arterial thromboembolism may also occur in association with thalidomide. Some patients continued thalidomide after the event, together with warfarin, with no further thromboembolism.
[1]
B. Barlogie,et al.
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
,
2001,
Blood.
[2]
J Shaughnessy,et al.
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.
,
2001,
Blood.
[3]
S. Rajkumar,et al.
Deep venous thrombosis and thalidomide therapy for multiple myeloma.
,
2001,
The New England journal of medicine.
[4]
F. Carsuzaa,et al.
Thalidomide et thromboses
,
2000
.
[5]
J. V. Sørensen,et al.
Venous thromboembolism and cancer.
,
1992,
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.